Researchers assessed the feasibility of using large language models to match cancer patients with certain genetic mutations to appropriate clinical trials.

In terms of locoregional recurrence, risk remains low when patients are treated with RT tailored to their individual risk.

Elevated respiratory pulse envelope amplitudes (AF RPE) independently distinguished primary central nervous system lymphoma (PCNSL) from healthy states and are associated with mortality, supporting ...

In this phase 3 trial, researchers sought to determine whether the combination of ceralasertib plus durvalumab would improve NSCLC outcomes compared to docetaxel.

Umbilical cord blood stem cell microtransplantation combined with chemotherapy significantly prolonged disease-free survival (DFS) in patients with acute myeloid leukemia (AML) and high-risk ...

A multicenter, single-arm, phase 2 trial investigated the activity and safety of varnimcabtagene autoleucel in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Investigators sought to determine whether weight-based dosing of pembrolizumab could produce outcomes similar to standard fixed dosing for patients with NSCLC.

Nutritional decline was most pronounced early in therapy. Weight nadirs most commonly occurred on days 8 (21.6%), 22 (22.9%), and 35 (21.6%), while TSFT nadirs clustered on day 8 (31.6%) and day 15 ...

Investigators sought to identify risks of prescription drug promotion by social media influencers and how current evidence can inform future research and effective policy ...

ART can safely replace ALND, with no axillary recurrences, and fewer cases of lymphedema in patients with breast cancer.

In the phase 2 ETOP ADEPPT trial, researchers sought to determine whether adagrasib, a KRAS G12C inhibitor, was effective in older patients and those with ECOG PS 2.

(HealthDay News) — The U.S. Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer. The agency sent ...